06/16/2025
A recent analysis by the Ethics and Public Policy Center (EPPC) has raised significant concerns about the safety of the abortion pill regimen, highlighting potential harm to women. The review examined data from the all-payer insurance claims database, covering 865,727 chemical abortions prescribed between 2017 and 2023. It found that 94,605 women experienced serious adverse events — meaning more than 1 in 10 women faced complications from mifepristone. According to this analysis, the actual rate of adverse outcomes is 22 times higher than what the FDA has reported. Nearly 11% of women who took mifepristone reportedly suffered from sepsis, infection, hemorrhage, or other serious complications within 45 days of use.
Mifepristone is the first drug used in the two-step chemical abortion process. Within 72 hours, it is followed by misoprostol, which induces intense contractions to expel the pregnancy. This often occurs at home, typically in a bathroom, without medical supervision — a setting that may leave women vulnerable in the event of complications.
Under the Obama and Biden administrations, the FDA rolled back several safeguards originally in place. These included the removal of Risk Evaluation and Mitigation Strategy (REMS) requirements for reporting adverse effects, as well as the elimination of in-person evaluations before prescribing the drug — a critical step for identifying conditions such as ectopic pregnancy. The FDA also ended the requirement for in-person follow-up care and even lifted the mandate for physician involvement at any stage of the chemical abortion process.
It’s essential that women are informed with accurate, up-to-date information when making such serious decisions.
We are here to help. Visit this link: https://ccconnectcare.as.me/schedule/0071404d to book a no-cost, confidential appointment right online at a time and location that works best for you!
